Redefining Omalizumab Discontinuation in Chronic Spontaneous Urticaria: The Value of Optimization and Predictive Factors of Relapse. A 52-Week Multicenter Study

Optimization seems to reduce the relapse rate after discontinuation. The most relevant factors for recurrence are associated with the duration of treatment at different doses of omalizumab, along with the baseline CRP and total IgE levels. To minimize relapse after suspension, a 12-month treatment regimen at 300mg/4 weeks followed by an 18-month dose tapering is proposed.